Pre-Market & FDA: What to Know Today

Don’t want emails from us anymore? Click here to unsubscribe

Hello Part-time Trader…👋

Premium Stock Alerts is here with your pre-market cheat sheet. In today's issue, we delve into:

  • Fed's Latest Announcements: Understand the Federal Reserve's recent decisions and economic outlook, and how they might influence the markets.

  • Volume Anomalies: Identify stocks witnessing unusual trading volumes, pointing to potential opportunities or risks.

  • Top Pre-Market Movers: Identify early winners poised for a strong market opening.

  • Market Indices & Sector Overview: Get a snapshot of key market indices and sector performances to gauge the day's potential trends.

  • FDA Approvals & Upcoming Decisions: Keep an eye on the latest FDA approvals and crucial upcoming decisions affecting biotech and pharmaceutical stocks.

Now, let's dive into today's edition for a closer look at the insights and analysis that will shape your trading decisions.


Bank of America Analysts Say this AI Company Could Grow 400% in the Next 3 Years

Some analysts say this company's 900% growth in the last year is a "one-and-done" pop, but Bank of America analysts disagree. In fact, they say it could go 4x higher in the next 3 years.

Click Here for the Stock Bank of America Says Could Quintuple Revenues 4x Over the Next 3 Years!

Happening Today

✓ 08:55 AM ET – Redbook (YoY)

✓ 10:00 AM ET – IBD/TIPP Economic Optimism (May)

✓ 11:30 AM ET – FOMC Member Kashkari Speaks

✓ 12:00 PM ET – EIA Short-Term Energy Outlook

✓ 01:00 PM ET – 3-Year Note Auction

✓ 03:00 PM ET – Consumer Credit (Mar)

✓ 04:30 PM ET – API Weekly Crude Oil Stock


Stock Futures hint at a positive open with NASDAQ 100 surging over 1.19%.



⬆️ 1.03%



⬆️ 0.46%



⬆️ 1.19% 


Tech stocks are on fire, leading the sector surge with a jump of nearly 1.5% today.




Consumer Discretionary


+1.06% 🟢

Consumer Staples


+0.08% 🟢



+0.82% 🟢



+1.17% 🟢

Health Care


+0.44% 🟢



+1.00% 🟢



+0.63% 🟢

Real Estate


-0.02% 🔴

Information Technology


+1.48% 🟢

Communication Services


+1.39% 🟢



+0.45% 🟢


NOW is the time to get in on this trillion-dollar megatrend 

Now is the time to position yourself for the next round of explosive growth from what will soon be a trillion-dollar market. But don't chase yesterday's winners!

The AI hype is off the charts and some AI stocks have run so far that they are looking WAY overvalued. When they crash back down to earth, some investors could get hurt. I don't want that to happen to you! So I'm making our new special report on the best AI stocks to own now free for a limited time. 

Get it here.

Unusual Volume

📈 Lyra Therapeutics Inc (LYRA) declined -87.06% to $0.52 on a whopping 108.03 million shares traded after it announced topline results from phase 3 ENLIGHTEN 1 trial for LYR-210 in Chronic Rhinosinusitis.

📈 Investors went wild, sending Strong Global Entertainment Inc (SGE) stock soaring 132.44% to $2.65 on a massive volume of 74.75 million shares after the company declared the proposed acquisition of Strong/MDI Screen Systems, Inc.

📈 Abnormal activity shook Workhorse Group Inc (WKHS), pushing it up 20.50% to $0.19 on a whopping 56.05 million shares traded.

📈 XBP Europe Holdings Inc (XBP) stock recently closed 65.09% upper at $3.50 on substantial volume of 55.61 million shares.

📈 Gamestop Corporation (GME) decrease by -0.97% in a single trading session, with abnormally high trading volume of 47.94 million shares.


FREE Investor Report: Zacks' 7 Best Stocks for May

Since 1988, Zacks' objective, mathematical stock prediction system has beaten the market consistently and convincingly.

This just-released Special Report reveals the 7 most explosive stocks from the list of current Zacks Rank #1 Strong Buys.

Less than 5% of stocks meet the criteria to be one of our "7 Best." Discover these recommended stock picks before your next trade.

Download it here, absolutely FREE

Premarket Movers

reAlpha Tech Corp. (AIRE) experiences a substantial 44.78% surge in pre-market trading after completing the acquisition of Naamche.

Esperion Therapeutics, Inc. (ESPR) sees a significant 19.76% increase, reaching a pre-market price of $2.53 after reporting Q1 2024 financial results.

Hims & Hers Health, Inc. (HIMS) demonstrates a noteworthy 12.70% surge, with a pre-market price of $13.13 after releasing Q1 2024 financial results.

Pre Market Gainers

Pre Market Change

Pre Market Volume
































The Dividend Stock to Leave for Your Grandchildren

Are you tired of your so-called "safe" income stocks slashing dividends while the share prices fall? I just revealed my safest most reliable and most consistent dividend stock - and it pays a sky high yield with dividends paid EVERY month. This company has also increased its monthly dividend twice a year every year for the past 8 years.

Tap here to reveal the name of this stock for free.

Important FDA 

Recently Announced

Day One Biopharmaceuticals (DAWN) is celebrating a major victory with the FDA approval of their drug Tovorafenib, now marketed under the brand name OJEMDA. This medication brings new hope to children battling a specific type of brain tumor: relapsed or progressive pediatric low-grade glioma.

X Pharmaceuticals (XFOR) can also clink glasses as their drug Mavorixafor, now known as XOLREMDI, received the FDA's green light. This medication offers a new approach to treating WHIM syndrome, a rare and difficult condition affecting people twelve and older.

Neurocrine Biosciences Inc (NBIX) has expanded the reach of their existing medication Ingrezza. The FDA recently approved a new sprinkle formulation, making it more convenient for adults with tardive dyskinesia and chorea associated with Huntington's disease to take their medication.

Upcoming Announcements

May 9th: Pfizer (PFE) is on pins and needles awaiting the FDA's verdict on their full approval application (sBLA) for Tivdak in treating a specific type of recurrent or metastatic cervical cancer. Tivdak currently holds only accelerated approval.

May 12th: All eyes are on Moderna, Inc (MRNA) as the FDA weighs their BLA for mRNA-1345, a vaccine targeting the respiratory syncytial virus (RSV). This vaccine has the potential to be a game-changer in public health.

May 13th: Dynavax Technologies Corp (DVAX) hopes for positive news from the FDA regarding their BLA for HEPLISAV-B, a hepatitis B vaccine. This application seeks to expand the vaccine's use to adults undergoing hemodialysis, a group at high risk for the disease.

🎁 Looking for More? Check out these complementary newsletters for diverse perspectives:

Bullseye Trades Get free daily HOT STOCK & Options trading ideas with real-money 💰 TRADE ALERTS from trading genius, Jeff Bishop
Market BriefingGet the briefing Wall Street & C-Suites are reading.

Happy investing,

Maeve Grace
Editor In Chief
Premium Trade Alerts

Important: This newsletter does not provide investment advice. The stocks mentioned should not be taken as recommendations. Your investments are solely your decisions.

Disclosure: I hold no positions in any companies mentioned, either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in this article.

Join the conversation

or to participate.